Genentech’s Lucentis® (ranibizumab injection) 0.3 mg is now approved for the monthly treatment of all forms of diabetic retinopathy. Diabetic retinopathy is the most common cause of vision loss in people with diabetes and the leading cause of blindness among adults aged 20 to 74. Lucentis is the first and only medicine FDA-approved to treat all forms of diabetic retinopathy. The FDA granted Lucentis Priority Review based on an analysis of the NIH-funded Diabetic Retinopathy Clinical Research Network’s (DRCR.net) Protocol S study, which compared Lucentis treatment to panretinal laser treatment in diabetic retinopathy patients both with and without diabetic macular edema (DME), a complication of diabetic retinopathy that causes swelling in the back of the eye. Priority Review Designation is granted to medicines that the FDA has determined to have the potential to provide significant improvements in the safety and effectiveness of the treatment of a serious disease. In February 2015, Lucentis received FDA approval for the treatment of diabetic retinopathy in people with DME based on data from the pivotal RIDE and RISE Phase III clinical trials. In the analysis that supported today’s approval, patients both with and without DME in the Lucentis group experienced improvements in the severity of their retinopathy. Diabetic retinopathy affects nearly 7.7 million people in the U.S. This is the second FDA approval for Lucentis this year. In January, Genentech announced the approval of Lucentis for myopic choroidal neovascularization (mCNV), the first FDA-approved medicine to treat patients with mCNV in the U.S.